{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:07:18Z","timestamp":1789542438763,"version":"build-2803163510"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Several issues have been identified with the current programs for the elimination of onchocerciasis that target only transmission by using mass drug administration (MDA) of the drug ivermectin. Alternative and\/or complementary treatment regimens as part of a more comprehensive strategy to eliminate onchocerciasis are needed. We posit that the addition of \u201cprophylactic\u201d drugs or therapeutic drugs that can be utilized in a prophylactic strategy to the toolbox of present microfilaricidal drugs and\/or future macrofilaricidal treatment regimens will not only improve the chances of meeting the elimination goals but may hasten the time to elimination and also will support achieving a sustained elimination of onchocerciasis. These \u201cprophylactic\u201d drugs will target the infective third- (L3) and fourth-stage (L4) larvae of <jats:italic>Onchocerca volvulus<\/jats:italic> and consequently prevent the establishment of new infections not only in uninfected individuals but also in already infected individuals and thus reduce the overall adult worm burden and transmission. Importantly, an effective prophylactic treatment regimen can utilize drugs that are already part of the onchocerciasis elimination program (ivermectin), those being considered for MDA (moxidectin), and\/or the potential macrofilaricidal drugs (oxfendazole and emodepside) currently under clinical development. Prophylaxis of onchocerciasis is not a new concept. We present new data showing that these drugs can inhibit L3 molting and\/or inhibit motility of L4 at IC<jats:sub>50<\/jats:sub> and IC<jats:sub>90<\/jats:sub> that are covered by the concentration of these drugs in plasma based on the corresponding pharmacological profiles obtained in human clinical trials when these drugs were tested using various doses for the therapeutic treatments of various helminth infections.<\/jats:p>","DOI":"10.1371\/journal.pntd.0009064","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T18:24:17Z","timestamp":1613672657000},"page":"e0009064","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis"],"prefix":"10.1371","volume":"15","author":[{"given":"Shabnam","family":"Jawahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-7062","authenticated-orcid":true,"given":"Nancy","family":"Tricoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2359-8354","authenticated-orcid":true,"given":"Christina A.","family":"Bulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3895-2982","authenticated-orcid":true,"given":"Judy","family":"Sakanari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-6113","authenticated-orcid":true,"given":"Sara","family":"Lustigman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"pntd.0009064.ref001","unstructured":"Onchocerciasis. Keys Facts. [Internet]. 2018 [cited 2019 May 26]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/onchocerciasis."},{"key":"pntd.0009064.ref002","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.12688\/gatesopenres.13067.1","article-title":"The World Health Organization 2030 goals for onchocerciasis: Insights and perspectives from mathematical modelling: NTD Modelling Consortium Onchocerciasis Group","volume":"3","author":"NTD Modelling Consortium Onchocerciasis Group","year":"2019","journal-title":"Gates Open Res"},{"issue":"1","key":"pntd.0009064.ref003","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40249-019-0557-1","article-title":"Elimination of onchocerciasis in Africa by 2025: the need for a broad perspective","volume":"8","author":"E Cupp","year":"2019","journal-title":"Infect Dis Poverty"},{"issue":"Suppl 1","key":"pntd.0009064.ref004","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1179\/136485908X337454","article-title":"The Onchocerciasis Elimination Program for the Americas (OEPA)","volume":"102","author":"M. Sauerbrey","year":"2008","journal-title":"Ann Trop Med Parasitol"},{"issue":"3","key":"pntd.0009064.ref005","first-page":"13","article-title":"Onchocerciasis control: the APOC strategy","volume":"19","author":"KY Dadzie","year":"1997","journal-title":"Afr Health"},{"issue":"Suppl 1","key":"pntd.0009064.ref006","doi-asserted-by":"crossref","first-page":"i14","DOI":"10.1093\/inthealth\/ihx052","article-title":"Onchocerciasis: shifting the target from control to elimination requires a new first-step-elimination mapping","volume":"10","author":"MP Rebollo","year":"2018","journal-title":"Int Health"},{"issue":"12","key":"pntd.0009064.ref007","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1093\/cid\/cix616","article-title":"Macrofilaricidal Efficacy of Repeated Doses of Ivermectin for the Treatment of River Blindness","volume":"65","author":"M Walker","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pntd.0009064.ref008","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1442-9071.1989.tb00567.x","article-title":"Ivermectin treatment of onchocerciasis","volume":"17","author":"HR Taylor","year":"1989","journal-title":"Aust N Z J Ophthalmol"},{"issue":"5","key":"pntd.0009064.ref009","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(08)70099-9","article-title":"Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis","volume":"8","author":"MG Bas\u00e1\u00f1ez","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"39","key":"pntd.0009064.ref010","doi-asserted-by":"crossref","first-page":"16716","DOI":"10.1073\/pnas.0906176106","article-title":"Identifying sub-optimal responses to ivermectin in the treatment of River Blindness","volume":"106","author":"TS Churcher","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pntd.0009064.ref011","doi-asserted-by":"crossref","first-page":"461","DOI":"10.4269\/ajtmh.1998.58.461","article-title":"Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis","volume":"58","author":"M Boussinesq","year":"1998","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"pntd.0009064.ref012","doi-asserted-by":"crossref","first-page":"e0003664","DOI":"10.1371\/journal.pntd.0003664","article-title":"Control, elimination, and eradication of river blindness: scenarios, timelines, and ivermectin treatment needs in Africa","volume":"9","author":"YE Kim","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"7","key":"pntd.0009064.ref013","doi-asserted-by":"crossref","first-page":"e0008427","DOI":"10.1371\/journal.pntd.0008427","article-title":"Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro","volume":"14","author":"MP Hubner","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0009064.ref014","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/acsinfecdis.9b00469","article-title":"Macrofilaricides: An Unmet Medical Need for Filarial Diseases","volume":"6","author":"NA Hawryluk","year":"2020","journal-title":"ACS Infect Dis."},{"issue":"1","key":"pntd.0009064.ref015","doi-asserted-by":"crossref","first-page":"e0006436","DOI":"10.1371\/journal.pntd.0006436","article-title":"Flubendazole as a macrofilaricide: History and background","volume":"13","author":"TG Geary","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"10154","key":"pntd.0009064.ref016","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0140-6736(18)30101-6","article-title":"A new powerful drug to combat river blindness","volume":"392","author":"M. Boussinesq","year":"2018","journal-title":"Lancet"},{"issue":"10154","key":"pntd.0009064.ref017","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"NO Opoku","year":"2018","journal-title":"Lancet"},{"key":"pntd.0009064.ref018","first-page":"1","article-title":"Moxidectin: an oral treatment for human onchocerciasis","volume":"2020","author":"P Milton","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"pntd.0009064.ref019","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1186\/s13071-019-3685-3","article-title":"Preventive efficacy of oral moxidectin at various doses and dosage regimens against macrocyclic lactone-resistant heartworm (Dirofilaria immitis) strains in dogs","volume":"12","author":"TL McTier","year":"2019","journal-title":"Parasit Vectors"},{"key":"pntd.0009064.ref020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpddr.2019.06.002","article-title":"Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance","volume":"10","author":"RK Prichard","year":"2019","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"pntd.0009064.ref021","unstructured":"Oxfendazole. Available from: https:\/\/www.dndi.org\/diseases-projects\/portfolio\/oxfendazole\/."},{"key":"pntd.0009064.ref022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-animal-021815-111209","article-title":"Lessons from the History of Ivermectin and Other Antiparasitic Agents","volume":"4","author":"WC Campbell","year":"2016","journal-title":"Annu Rev Anim Biosci"},{"issue":"1","key":"pntd.0009064.ref023","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4269\/ajtmh.1988.39.86","article-title":"Ivermectin prophylaxis against experimental Onchocerca volvulus infection in chimpanzees","volume":"39","author":"HR Taylor","year":"1988","journal-title":"Am J Trop Med Hyg"},{"issue":"Pt 2","key":"pntd.0009064.ref024","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1017\/S0031182098003680","article-title":"Chemoprophylaxis of Onchocerca infections: in a controlled, prospective study ivermectin prevents calves becoming infected with O. ochengi","volume":"118","author":"VL Tchakoute","year":"1999","journal-title":"Parasitology"},{"issue":"9","key":"pntd.0009064.ref025","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.ijpara.2004.04.011","article-title":"Cattle protected from onchocerciasis by ivermectin are highly susceptible to infection after drug withdrawal","volume":"34","author":"LM Njongmeta","year":"2004","journal-title":"Int J Parasitol"},{"issue":"1","key":"pntd.0009064.ref026","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s13071-020-04126-x","article-title":"Individuals living in an onchocerciasis focus and treated three-monthly with ivermectin develop fewer new onchocercal nodules than individuals treated annually","volume":"13","author":"JT Campillo","year":"2020","journal-title":"Parasit Vectors"},{"key":"pntd.0009064.ref027","first-page":"167","article-title":"The potential impact of moxidectin on onchocerciasis elimination in Africa: an economic evaluation based on the Phase II clinical trial data","volume":"8","author":"HC Turner","year":"2015"},{"issue":"2","key":"pntd.0009064.ref028","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1021\/acsinfecdis.9b00396","article-title":"Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 1. Amide Linked Analogs","volume":"6","author":"T Akama","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"2","key":"pntd.0009064.ref029","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/acsinfecdis.9b00397","article-title":"Macrofilaricidal Benzimidazole-Benzoxaborole Hybrids as an Approach to the Treatment of River Blindness: Part 2. Ketone Linked Analogs","volume":"6","author":"DS Carter","year":"2020","journal-title":"ACS Infect Dis"},{"issue":"1","key":"pntd.0009064.ref030","doi-asserted-by":"crossref","first-page":"e0007108","DOI":"10.1371\/journal.pntd.0007108","article-title":"Development of a preliminary in vitro drug screening assay based on a newly established culturing system for pre-adult fifth-stage Onchocerca volvulus worms","volume":"13","author":"D Voronin","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0009064.ref031","doi-asserted-by":"crossref","first-page":"e0003534","DOI":"10.1371\/journal.pntd.0003534","article-title":"Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis","volume":"9","author":"CA Bulman","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"pntd.0009064.ref032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cpdd.81","article-title":"Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects","volume":"3","author":"JM Korth-Bradley","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"pntd.0009064.ref033","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s002280050131","article-title":"Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus","volume":"50","author":"OZ Baraka","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"pntd.0009064.ref034","doi-asserted-by":"crossref","first-page":"e2953","DOI":"10.1371\/journal.pntd.0002953","article-title":"A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.","volume":"8","author":"K Awadzi","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"pntd.0009064.ref035","doi-asserted-by":"crossref","first-page":"e0006296","DOI":"10.1371\/journal.pntd.0006296","article-title":"Review of the 2017 WHO Guideline: Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups. An opportunity lost in translation","volume":"12","author":"L Savioli","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0009064.ref036","doi-asserted-by":"crossref","first-page":"e3328","DOI":"10.1371\/journal.pntd.0003328","article-title":"Global programme to eliminate lymphatic filariasis: the processes underlying programme success","volume":"8","author":"K Ichimori","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0009064.ref037","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/14787210.2018.1555241","article-title":"Oxfendazole: a promising agent for the treatment and control of helminth infections in humans.","volume":"17","author":"AE Gonzalez","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"pntd.0009064.ref038","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1007\/s00436-009-1492-z","article-title":"Field evaluation of the efficacy and safety of emodepside plus praziquantel tablets (Profender tablets for dogs) against naturally acquired nematode and cestode infections in dogs","volume":"105","author":"G Altreuther","year":"2009","journal-title":"Parasitol Res"},{"issue":"Suppl 1","key":"pntd.0009064.ref039","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1007\/s00436-009-1491-0","article-title":"Efficacy of emodepside plus praziquantel tablets (Profender tablets for dogs) against mature and immature adult Trichuris vulpis infections in dogs","volume":"105","author":"A Schimmel","year":"2009","journal-title":"Parasitol Res"},{"issue":"Suppl 1","key":"pntd.0009064.ref040","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1007\/s00436-015-4521-0","article-title":"Efficacy of Emodepside\/Praziquantel Spot-on (Profender(R)) against adult Aelurostrongylus abstrusus Nematodes in Experimentally Infected Cats","volume":"114","author":"C Bohm","year":"2015","journal-title":"Parasitol Res"},{"issue":"4","key":"pntd.0009064.ref041","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02489-18","article-title":"Pharmacokinetics of Albendazole, Albendazole Sulfoxide, and Albendazole Sulfone Determined from Plasma, Blood, Dried-Blood Spots, and Mitra Samples of Hookworm-Infected Adolescents","volume":"63","author":"JD Schulz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pntd.0009064.ref042","article-title":"Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Volunteers: a Randomized, Placebo-Controlled First-in-Human Single-Dose Escalation Study","volume":"63","author":"G An","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0009064.ref043","unstructured":"ClinicalTrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02661178."},{"issue":"Suppl 1","key":"pntd.0009064.ref044","doi-asserted-by":"crossref","first-page":"i28","DOI":"10.1093\/inthealth\/ihv077","article-title":"Neglected tropical diseases in Africa: a new paradigm","volume":"8","author":"AD Hopkins","year":"2016","journal-title":"Int Health"},{"issue":"9","key":"pntd.0009064.ref045","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1371\/journal.pntd.0000293","article-title":"Impact of long-term treatment with ivermectin on the prevalence and intensity of soil-transmitted helminth infections.","volume":"2","author":"AL Moncayo","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0009064.ref046","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S1473-3099(18)30233-0","article-title":"Efficacy and tolerability of moxidectin alone and in co-administration with albendazole and tribendimidine versus albendazole plus oxantel pamoate against Trichuris trichiura infections: a randomised, non-inferiority, single-blind trial","volume":"18","author":"B Barda","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"pntd.0009064.ref047","doi-asserted-by":"crossref","first-page":"e0008322","DOI":"10.1371\/journal.pntd.0008322","article-title":"The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Democratic Republic of the Congo","volume":"14","author":"SDS Pion","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0009064.ref048","doi-asserted-by":"crossref","first-page":"e948","DOI":"10.1371\/journal.pntd.0000948","article-title":"Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic","volume":"5","author":"J Vercruysse","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0009064.ref049","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s13071-019-3476-x","article-title":"Evaluation of emodepside in laboratory models of human intestinal nematode and schistosome infections.","volume":"12","author":"T Karpstein","year":"2019","journal-title":"Parasit Vectors"},{"issue":"7","key":"pntd.0009064.ref050","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(17)30175-5","article-title":"Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo","volume":"17","author":"SDS Pion","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pntd.0009064.ref051","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-018-2558-3","article-title":"High Throughput and Computational Repurposing for Neglected Diseases","volume":"36","author":"HW Hernandez","year":"2018","journal-title":"Pharm Res"},{"issue":"3","key":"pntd.0009064.ref052","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijpddr.2014.09.001","article-title":"Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis","volume":"4","author":"KL Johnston","year":"2014","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"3","key":"pntd.0009064.ref053","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijpddr.2014.07.002","article-title":"Repurposing drugs for the treatment and control of helminth infections","volume":"4","author":"G Panic","year":"2014","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"3","key":"pntd.0009064.ref054","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ijpddr.2016.04.002","article-title":"Research for new drugs for elimination of onchocerciasis in Africa","volume":"6","author":"AC Kuesel","year":"2016","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"11","key":"pntd.0009064.ref055","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1093\/infdis\/jiz307","article-title":"Integrating Multiple Biomarkers to Increase Sensitivity for the Detection of Onchocerca volvulus Infection","volume":"221","author":"S Bennuru","year":"2020","journal-title":"J Infect Dis"},{"key":"pntd.0009064.ref056","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/bs.apar.2016.08.003","article-title":"River Blindness: Mathematical Models for Control and Elimination","volume":"94","author":"MG Basanez","year":"2016","journal-title":"Adv Parasitol"},{"issue":"Suppl 4","key":"pntd.0009064.ref057","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1093\/cid\/cix1137","article-title":"How Can Onchocerciasis Elimination in Africa Be Accelerated? Modeling the Impact of Increased Ivermectin Treatment Frequency and Complementary Vector Control","volume":"66","author":"S Verver","year":"2018","journal-title":"Clin Infect Dis"},{"key":"pntd.0009064.ref058","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s13071-015-1159-9","article-title":"Required duration of mass ivermectin treatment for onchocerciasis elimination in Africa: a comparative modelling analysis","volume":"8","author":"WA Stolk","year":"2015","journal-title":"Parasit Vectors"},{"issue":"7","key":"pntd.0009064.ref059","doi-asserted-by":"crossref","first-page":"e0003938","DOI":"10.1371\/journal.pntd.0003938","article-title":"Human Onchocerciasis: Modelling the Potential Long-term Consequences of a Vaccination Programme","volume":"9","author":"HC Turner","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"12","key":"pntd.0009064.ref060","doi-asserted-by":"crossref","first-page":"e115886","DOI":"10.1371\/journal.pone.0115886","article-title":"Elimination of African onchocerciasis: modeling the impact of increasing the frequency of ivermectin mass treatment","volume":"9","author":"LE Coffeng","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"pntd.0009064.ref061","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1038\/s41467-020-16442-y","article-title":"Designing antifilarial drug trials using clinical trial simulators","volume":"11","author":"M Walker","year":"2020","journal-title":"Nat Commun."},{"issue":"4","key":"pntd.0009064.ref062","doi-asserted-by":"crossref","first-page":"e0008033","DOI":"10.1371\/journal.pntd.0008033","article-title":"Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium","volume":"14","author":"MR Behrend","year":"2020","journal-title":"PLoS Negl Trop Dis"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T18:25:10Z","timestamp":1613672710000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0009064"}},"subtitle":[],"editor":[{"given":"Sabine","family":"Specht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0009064","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]}}}